Transcatheter aortic-valve implantation has developed rapidly as an alternative to surgical valve replacement, with two relatively mature technologies in clinical use.
Discusses the historical development and clinical emergence of transcatheter aortic-valve implantation technologies.
In 2000, Bonhoeffer et al. described transvenous placement of a pulmonary-valve prosthesis and speculated that similar technology might be used in other cardiac valves, including the aortic position.1 Two years later, the first transcatheter insertion of an aortic-valve prosthesis was performed by Cribier et al.2 Transcatheter aortic-valve implantation has developed rapidly, and two relatively mature technologies are in clinical use: the SAPIEN Transcatheter Heart Valve (Edwards Lifesciences) and the CoreValve Revalving System (Medtronic). In contrast to surgical valve replacement, in which the diseased, calcified cusps are removed, these and other catheter-based techniques in development rely on forcibly spreading the stenotic . . .
Hartzell V. Schaff (Sun,) conducted a editorial in Aortic valve stenosis. Transcatheter aortic-valve implantation vs. Surgical valve replacement was evaluated. Transcatheter aortic-valve implantation has developed rapidly as an alternative to surgical valve replacement, with two relatively mature technologies in clinical use.